Ionis told investors in July that TRYNGOLZA was "on track" for $100 million to $110 million in 2026 sales. On November 9, it lowered that target to roughly $50 million. NEW YORK, Nov. 9, 2026 /PRNewswire/ --
PHILADELPHIA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company")
– ZANVASTRO™ (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline –
– TRYNGOLZA® (olezarsen) 2026 product sales guidance lowered as sHTG
Webcast scheduled for Monday, November 9 at 9:00 a.m. Eastern Time
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Monday, November 9 at 9:00 a.m. Eastern Time to discuss
– Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and pharmaceutical industries. Rising from
– Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care –
– Six-month treatment with option of at-home administration after first dose –
– CHB affects approximately 1.7
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the indication
– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –
– IgAN is a progressive kidney disease that is
– Ulefnersen demonstrated a statistically significant improvement on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the potential to modify disease
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the
- Provides a clinically meaningful impact on motor function and a favorable impact on other symptoms seen in AxD, an ultra-rare, progressive and often fatal neurological disorder -
- Priority Review Voucher (PRV)
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will participate in fireside chats at the following investor conferences:
21st Annual Wells Fargo Healthcare Conference on Thursday,
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or
